激素受体阳性人表皮生长因子受体2阳性乳腺癌分子分型与异质性的研究进展

Progress of molecular typing and heterogeneity in hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer

激素受体阳性人表皮生长因子受体2阳性(HR+HER2+)乳腺癌是一类具有高度异质性的疾病,约占乳腺癌10%。各亚型的分子生物学特征、药物治疗疗效及预后有显著差异。文章将以异质性为切入点,对HR+HER2+乳腺癌的分子生物学特征、诊疗现状及单细胞水平研究进展进行综述。

Hormone receptor-positive and human epidermal growth factor receptor 2-positive(HR+HER2+)breast cancer is a highly heterogeneous disease,accounting for about 10%of breast cancers.The molecular biological characteristics,therapeutic effect and prognosis of all subtypes have significant differences.This paper reviews the research progress of molecular biological characteristics,diagnosis and treatment condition and single-cell level in HR+HER2+breast cancer from the perspective of heterogeneity.